Physician profile
Daniel Branham
NPI 1467661223
$18,689.73
in general payments reported to CMS, 2019-2025
16 companies · $240 in 2025
The $240 reported for 2025 was less than what a typical Hand Surgery provider received nationally (typical 2025 total: $270).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13K · 2020: $3,033 · 2021: $1,727 · 2022: $242 · 2023: $130 · 2024: $305 · 2025: $240.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $675.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $675.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medartis INC. | $11,309.06 | 2019-2020 | |
| Alpha Orthopedic Systems | $3,606.97 | 2019-2022 | |
| Arthrex, INC. | $2,722.84 | 2019-2021 | |
| Smoky Mountain Surgical LLC | $477.54 | 2023-2025 | |
| Abbott Laboratories | $149.69 | 2022-2024 | Proclaim, Eterna |
| Stryker Corporation | $122.44 | 2019 | |
| Amgen INC. | $52.93 | 2019 | |
| Smith+Nephew, INC. | $52.34 | 2019-2025 | Grafix Pl, Stravix Pl |
| Axogen | $51.36 | 2022 | |
| Endo Pharmaceuticals INC. | $48.47 | 2022-2023 | Xiaflex |
| Horizon Therapeutics Plc | $26.80 | 2020-2022 | |
| Boston Scientific Corporation | $22.32 | 2025 | Wavewriter Alpha Prime 16 |
| Vertex Pharmaceuticals Incorporated | $18.95 | 2025 | |
| Radius Health, INC. | $15.53 | 2020 | |
| Pacira Therapeutics, INC. | $12.49 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$166,393.42 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Branham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.